Overactive Bladder
A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder.
February 11, 2024
Microstructural white matter abnormalities in overactive bladder syndrome evaluation with diffusion kurtosis imaging tract-based spatial statistics analysis.
February 11, 2024
Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection.
February 11, 2024
Exploring lifelong overactive bladder: Transitions, evidence, and clinical implications; A modified Delphi process.
February 4, 2024
Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment.
February 4, 2024
Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists.
January 28, 2024
What is the best first choice oral drug therapy for OAB?
January 28, 2024
Clinical tools for evaluating the severity of overactive bladder: A systematic review of psychometric properties.
January 21, 2024
Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA Registry.
January 21, 2024
Current optimal pharmacologic therapies for overactive bladder.
January 14, 2024
Real-World Evidence for Risk Factors of Bruises and Fractures from Falls in Patients with Overactive Bladder: A Medical Record Analysis.
January 7, 2024
How I Do It: Transcutaneous tibial nerve stimulation TENSI+ system.
December 31, 2023